Sector Alpha Week of 2026-09-17
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-17

Symbotic Inc.

SYM
Industrials · Specialty Industrial Machinery

Symbotic Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.

The price is in a downtrend (1 weeks in). Underneath, the last four quarters read improving. What settles it: the next one or two quarters of delivery.

Price
$43.1
−24.4% 1Y
P/E
730.4×
vs its own history
Revenue (Jun 26)
$0.7 B
+22.0% YoY
Profit (Jun 26)
$0.0 B
Operating margin
4.2%
+5.9 pp YoY
ROE
4%
FY25
ROIC
1.1%
vs WACC 14.9% → −13.8 pp
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Symbotic Inc. trades at $43.1, in a downtrend and 1 weeks into that stage. That is −16.8% against its own 200-day average. It sits at 7% of a 52-week range of $40 to $84. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.

Today the stock is in a downtrend — week 1 of stage 4. At $43.1 it trades −16.8% versus its 200-day average and sits at 7% of its 52-week range ($40–$84).

Sep 26: $43.1 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−16.8% versus the 200-day line, week 1 of stage 4
Price50-day avg200-day avg
S2S1S4S4S3S2S1$89.1$69.9$50.6$31.4$12.2$$43$52Sep 23Jun 24Mar 25Dec 25Sep 26
S2S1S4S4S3S2S1$89.1$69.9$50.6$31.4$12.2$$43$52Sep 23Mar 25Sep 26
Beating or trailing, week by week since 2021 Each cell is one week from 2021 to now (289 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Mar 21Sep 26

Against the market, two honest reads. Cumulative: over the last 5.5 years the stock moved +313% while the S&P 500 moved +91% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Symbotic Inc. trades at 730.4× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 730.4× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.

PEG 0.25 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 6 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
5.2×3.9×2.6×1.3×0.0××0.25×Mar 25Jun 25Sep 25Dec 25Jun 26
5.2×3.9×2.6×1.3×0.0××0.25×Mar 25Sep 25Jun 26
P/E
730.4×
too little history to rank
PEG
2.08
as reported

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Symbotic Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Growth, year by year: revenue +25.7% in FY25 Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoY
145%113%81%49%17%%25.7%FY21FY23FY25
145%113%81%49%17%%25.7%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over
RevenueEPS
103%−108.1%81%−108.7%59%−109.3%37%−109.9%15%−110.5%%%21%−109.3%Sep 23Dec 24Jun 26
103%−108.1%81%−108.7%59%−109.3%37%−109.9%15%−110.5%%%21%−109.3%Sep 23Dec 24Jun 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
30%−60%−151%−242%−333%%5.3%Sep 23Mar 24Dec 24Sep 25Jun 26
30%−60%−151%−242%−333%%5.3%Sep 23Dec 24Jun 26
Revenue growth
Steady high
latest +21.0% · span +21.0% to +96.7%
ROCE
Rising
latest 5.3% · span −307.7%–5.3%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+25.7%+56.2%
Stock price−24.4%+10.6%+34.5%
Revenue YoY (Jun 26)
+22.0%
latest quarter vs a year ago
Revenue 10y
73.2%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

47.0/100 — rank 16 of 30 in Specialty Industrial Machinery · 67% evidence confidence

Symbotic Inc. scores 47.0 out of 100 against the 30 companies it is compared with in Specialty Industrial Machinery, ranking 16. Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.2% and the one-year return is -24.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.

The four contributions add to the total exactly: 26.3 + 5.8 + 8.6 + 6.3 = 47. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Symbotic Inc. reported $0.7 B of revenue in the Jun 26 quarter, +22.0% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 73.2% a year. The last full year, FY25, came in at $2.3 B. The last four reported quarters add to $2.7 B.

FY25 revenue came in at $2.3 B (+25.7% on the year), capping 4 years at 73.2% compound. The latest quarter (Jun 26) printed $0.7 B, +22.0% year on year — the 12th consecutive quarter of year-over-year growth.

FY25 revenue $2.3 B (+25.7% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
73.2% a year over 4 years
RevenueYoY growth
2.4145%1.8113%1.281%0.649%0.017%$ B%$2B25.7%FY21FY23FY25
2.4145%1.8113%1.281%0.649%0.017%$ B%$2B25.7%FY21FY23FY25
Jun 26: $0.7 B (+22.0% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
12th straight quarter of growth
Revenue (quarterly)YoY growth
0.876%0.659%0.441%0.223%0.05.8%$ B%$1B22%Sep 23Dec 24Jun 26
0.876%0.659%0.441%0.223%0.05.8%$ B%$1B22%Sep 23Dec 24Jun 26

Pace check: the last four quarters averaged +21.2% growth against the decade's 73.2% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +21.0% over the last 4 quarters against +28.3%/yr over the last 8 — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Symbotic Inc.'s operating margin is 4.2% in the Jun 26 quarter, +5.9 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −48.0% to −3.6%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 4.2%, +5.9 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −48.0%–−3.6%.

Why the margin moved: operating margin went +5.9 pp year on year while gross margin went +3.6 pp — the gain came mostly from the gross line: input costs and pricing.

FY25: −3.6% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a −48.0–−3.6% band over 5 years
operating marginYoY change (pp)
0.0%26%−13%19%−26%13%−39%5.8%−52%−1.0%%%−3.6%0.9%FY21FY23FY25
0.0%26%−13%19%−26%13%−39%5.8%−52%−1.0%%%−3.6%0.9%FY21FY23FY25
Jun 26: 4.2% operating margin (+5.9 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
5.4%27%1.2%19%−3.0%12%−7.3%3.8%−11%−3.9%%%4.2%5.9%Sep 23Dec 24Jun 26
5.4%27%1.2%19%−3.0%12%−7.3%3.8%−11%−3.9%%%4.2%5.9%Sep 23Dec 24Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Symbotic Inc. earned $0.0 B of net profit in the Jun 26 quarter. The full FY25 year was a loss of $0.02 B. That is 1.4% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 2 of the last 12 reported quarters were loss-making.

Jun 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $−0.0 B (null).

FY25 profit $−0.0 B (null YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profit
0.01−0.03−0.06−0.09−0.13$ B$0BFY21FY23FY25
0.01−0.03−0.06−0.09−0.13$ B$0BFY21FY23FY25
Jun 26: $0.0 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)
0.0120.0060.000−0.006−0.012$ B$0BSep 23Dec 24Jun 26
0.0120.0060.000−0.006−0.012$ B$0BSep 23Dec 24Jun 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Symbotic Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $0.9 B of operating cash against $−0.0 B of profit. After $0.1 B of capital spending, $0.8 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY25: operating cash of $0.9 B against reported profit of $−0.0 B, leaving free cash of $0.8 B after $0.1 B of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $0.9 B vs profit $−0.0 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
Operating cashNet profitFree cash
1.00.70.30.0−0.3$ B$1B$0B$1BFY21FY23FY25
1.00.70.30.0−0.3$ B$1B$0B$1BFY21FY23FY25
Jun 26: operating cash $−0.1 B = −1,500% of the quarter's profit Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.6228%0.4−236%0.2−700%0.0−1,164%−0.3−1,628%$ B%$−0B−1,500%Sep 23Dec 24Jun 26
0.6228%0.4−236%0.2−700%0.0−1,164%−0.3−1,628%$ B%$−0B−1,500%Sep 23Dec 24Jun 26

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Symbotic Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.1 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.090.060.040.020.00$ B$0BFY21FY23FY25
0.090.060.040.020.00$ B$0BFY21FY23FY25
Jun 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.040.50.030.30.020.10.01−0.10.00−0.3$ B$ B$0B$−0BSep 23Dec 24Jun 26
0.040.50.030.30.020.10.01−0.10.00−0.3$ B$ B$0B$−0BSep 23Dec 24Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Symbotic Inc. earns a ROE of −4% in FY25. That is up from a trough of −14% in FY22. Return on invested capital clears the cost of that capital by −13.8 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −0.9% net margin on 0.94× asset turns.

FY25 ROE is −4%, recovered from a FY22 trough of −14% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY25): −0.9% net margin × 0.94× asset turns × 5.00× balance-sheet leverage ≈ −4.2% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 1.1% − 14.9% = a −13.8 pp spread. The 14.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY25: ROE −4% Return on equity by fiscal year, % (line). 4-year window, dips included. Dashed line = the 14.9% cost of capital used on this page.
the climb back from FY22's −14%
ROEWACC
47%31%14%−2.3%−19%%−4.2%FY21FY22FY25
47%31%14%−2.3%−19%%−4.2%FY21FY22FY25
Jun 26: ROE −24.9% (TTM) Trailing-twelve-month ROE, per quarter, %. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROE (TTM)
271%−801%−1,873%−2,945%−4,016%%−24.9%Sep 23Dec 24Jun 26
271%−801%−1,873%−2,945%−4,016%%−24.9%Sep 23Dec 24Jun 26
11 · Dividend

Dividend

Symbotic Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Symbotic Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Debt-to-equity is 0.02 at the latest reading — effectively unlevered; a full borrowings history is not in our numbers.

We hold only the latest reading here: a debt-to-equity of 0.02 — the balance sheet is effectively unlevered, so the returns above are earned, not borrowed. A year-by-year borrowings ladder is not in our numbers for this stock, so we say that rather than draw a chart we cannot support.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

14.8% of Symbotic Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 9.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 14.8% of the float is sold short, and at typical trading volumes it would take about 9.6 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
14.8%
of the tradable float
Days to cover
9.6
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Symbotic Inc.: the Z-score reads 2.16. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 2.16 sits in the grey band — neither clearly safe nor clearly distressed.

The safety line in one sentence: the Z-score reads 2.16.

15 · Related companies · Specialty Industrial Machinery
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Watts Water Technologies, Inc.WTS 73.0/100Favorable setup81% evidence FADING 26.6/35 Revenue 14.3% · PAT 25.3% · OPM change 3.9 pp 83% evidence 14.3/25 ROCE 5.9% · OPM 19.6% 76% evidence 13.6/20 P/E 26.3× · PEG 1.04 65% evidence 18.5/20 RS sector 15.7% · RS bench 5.2% · 1Y 24.1%10 of 12 weeks ahead 100% evidence
Exact sum: 26.6 + 14.3 + 13.6 + 18.5 = 73 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Donaldson Company, Inc.DCI 64.2/100Mixed-positive evidence85% evidence ASLEEP 24.7/35 Revenue 4.4% · PAT 20.9% · OPM change 6.3 pp 95% evidence 14.3/25 ROCE 6.7% · OPM 15.6% 76% evidence 14.7/20 P/E 23.7× · PEG 0.95 65% evidence 10.5/20 RS sector -1.2% · RS bench -10.3% · 1Y 6.5%5 of 12 weeks ahead 100% evidence
Exact sum: 24.7 + 14.3 + 14.7 + 10.5 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Nordson CorporationNDSN 63.5/100Mixed-positive evidence85% evidence FADING 19.8/35 Revenue 7.4% · PAT 18.4% · OPM change 1.9 pp 95% evidence 12.8/25 ROCE 3.6% · OPM 26.6% 76% evidence 11.7/20 P/E 30.8× · PEG 1.5 65% evidence 19.2/20 RS sector 16.9% · RS bench 6.2% · 1Y 37.3%5 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 12.8 + 11.7 + 19.2 = 63.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Emerson Electric Co.EMR 59.2/100Mixed-positive evidence85% evidence ASLEEP 21.2/35 Revenue 4.8% · PAT 20.9% · OPM change 2.1 pp 95% evidence 13.8/25 ROCE 4.2% · OPM 26.9% 76% evidence 8.9/20 P/E 31.3× · PEG 2.1 65% evidence 15.3/20 RS sector 6.6% · RS bench -3.1% · 1Y 10.2%6 of 12 weeks ahead 100% evidence
Exact sum: 21.2 + 13.8 + 8.9 + 15.3 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5GE Vernova Inc.GEV 59.0/100Mixed-positive evidence85% evidence ASLEEP 26.8/35 Revenue 13% · PAT 100% · OPM change 1.6 pp 95% evidence 11.7/25 ROCE 10.9% · OPM 7.5% 76% evidence 7.0/20 P/E 33.1× · PEG 2.79 65% evidence 13.5/20 RS sector 14.3% · RS bench 3.8% · 1Y 48.2%1 of 12 weeks ahead 100% evidence
Exact sum: 26.8 + 11.7 + 7 + 13.5 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6IDEX CorporationIEX 57.3/100Thin evidence · provisional58% evidence FADING 18.1/35 Revenue — · PAT — · OPM change 2 pp 45% evidence 11.4/25 ROCE 3.1% · OPM 19.4% 76% evidence 10.1/20 P/E 32.7× · PEG — 15% evidence 17.7/20 RS sector 14.3% · RS bench 3.9% · 1Y 37.6%4 of 12 weeks ahead 100% evidence
Exact sum: 18.1 + 11.4 + 10.1 + 17.7 = 57.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Rockwell Automation, Inc.ROK 56.2/100Mixed-positive evidence85% evidence ASLEEP 23.7/35 Revenue 11.3% · PAT 13.9% · OPM change 3.2 pp 95% evidence 14.8/25 ROCE 6.4% · OPM 20.8% 76% evidence 8.8/20 P/E 46.4× · PEG 1.84 65% evidence 8.9/20 RS sector 4.2% · RS bench -5.2% · 1Y 19.3%5 of 12 weeks ahead 100% evidence
Exact sum: 23.7 + 14.8 + 8.8 + 8.9 = 56.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Illinois Tool Works Inc.ITW 56.2/100Mixed-positive evidence85% evidence FADING 13.8/35 Revenue 4.3% · PAT -5.1% · OPM change 0.3 pp 95% evidence 17.1/25 ROCE 10.1% · OPM 26.7% 76% evidence 11.0/20 P/E 24.5× · PEG 1.83 65% evidence 14.3/20 RS sector 4.3% · RS bench -5.3% · 1Y 2.1%5 of 12 weeks ahead 100% evidence
Exact sum: 13.8 + 17.1 + 11 + 14.3 = 56.2 · Decision use: Price leads the evidence: RS versus the benchmark is -5.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
9Dover CorporationDOV 53.5/100Mixed-positive evidence85% evidence ASLEEP 15.5/35 Revenue 7.5% · PAT -50.5% · OPM change 0.7 pp 95% evidence 17.7/25 ROCE 13.6% · OPM 18.7% 76% evidence 15.5/20 P/E 26.6× · PEG 0.22 65% evidence 4.8/20 RS sector -4.2% · RS bench -13.2% · 1Y 9.9%0 of 12 weeks ahead 100% evidence
Exact sum: 15.5 + 17.7 + 15.5 + 4.8 = 53.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
10AMETEK, Inc.AME 52.9/100Mixed-positive evidence85% evidence ASLEEP 18.4/35 Revenue 12.6% · PAT 9.7% · OPM change -0.2 pp 95% evidence 13.3/25 ROCE 3.9% · OPM 25.8% 76% evidence 5.5/20 P/E 35.4× · PEG 3.49 65% evidence 15.7/20 RS sector 8.8% · RS bench -1.2% · 1Y 23.6%1 of 12 weeks ahead 100% evidence
Exact sum: 18.4 + 13.3 + 5.5 + 15.7 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Graco Inc.GGG 51.7/100Thin evidence · provisional58% evidence ASLEEP 16.2/35 Revenue — · PAT — · OPM change -1.8 pp 45% evidence 15.4/25 ROCE 6.6% · OPM 25.5% 76% evidence 10.9/20 P/E 24× · PEG — 15% evidence 9.2/20 RS sector -4.5% · RS bench -13.3% · 1Y -9.9%0 of 12 weeks ahead 100% evidence
Exact sum: 16.2 + 15.4 + 10.9 + 9.2 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Otis Worldwide CorporationOTIS 50.6/100Mixed-positive evidence85% evidence ASLEEP 17.2/35 Revenue 5.2% · PAT 0.2% · OPM change -1.1 pp 95% evidence 19.4/25 ROCE 80.3% · OPM 15.1% 76% evidence 6.8/20 P/E 18.1× · PEG 4.62 65% evidence 7.2/20 RS sector -12.7% · RS bench -20.7% · 1Y -22.3%0 of 12 weeks ahead 100% evidence
Exact sum: 17.2 + 19.4 + 6.8 + 7.2 = 50.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
13Ingersoll Rand Inc.IR 50.5/100Mixed-positive evidence85% evidence ASLEEP 28.0/35 Revenue 7.8% · PAT 44.8% · OPM change 14.6 pp 95% evidence 10.5/25 ROCE 2.4% · OPM 18.6% 76% evidence 5.1/20 P/E 33.7× · PEG 5.21 65% evidence 6.9/20 RS sector -9.3% · RS bench -17.8% · 1Y -12.5%4 of 12 weeks ahead 100% evidence
Exact sum: 28 + 10.5 + 5.1 + 6.9 = 50.5 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.3% and the one-year return is -12.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
14Parker-Hannifin CorporationPH 50.0/100Mixed-positive evidence85% evidence FADING 19.5/35 Revenue 8.3% · PAT 3.3% · OPM change 2.6 pp 95% evidence 14.3/25 ROCE 5.7% · OPM 23.9% 76% evidence 4.6/20 P/E 34.3× · PEG 6.75 65% evidence 11.6/20 RS sector 4.2% · RS bench -5.4% · 1Y 21.6%5 of 12 weeks ahead 100% evidence
Exact sum: 19.5 + 14.3 + 4.6 + 11.6 = 50 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Xylem Inc.XYL 49.5/100Mixed-negative evidence85% evidence ASLEEP 20.4/35 Revenue 4.5% · PAT 8.5% · OPM change 2.7 pp 95% evidence 15.4/25 ROCE 9.6% · OPM 17% 76% evidence 6.9/20 P/E 27.6× · PEG 2.94 65% evidence 6.8/20 RS sector -13.5% · RS bench -21.4% · 1Y -24.9%1 of 12 weeks ahead 100% evidence
Exact sum: 20.4 + 15.4 + 6.9 + 6.8 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Symbotic Inc.this pageSYM 47.0/100Mixed-negative evidence67% evidence TURNING 26.3/35 Revenue 20.6% · PAT — · OPM change 6.1 pp 71% evidence 5.8/25 ROCE 3.5% · OPM 4.6% 76% evidence 8.6/20 P/E 415.7× · PEG — 15% evidence 6.3/20 RS sector -18.2% · RS bench -25.6% · 1Y -24.4%0 of 12 weeks ahead 100% evidence
Exact sum: 26.3 + 5.8 + 8.6 + 6.3 = 47 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.2% and the one-year return is -24.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
17Crane CompanyCR 47.0/100Thin evidence · provisional58% evidence ASLEEP 14.0/35 Revenue — · PAT — · OPM change -3.7 pp 45% evidence 10.8/25 ROCE 5.2% · OPM 14.4% 76% evidence 9.3/20 P/E 39× · PEG — 15% evidence 12.9/20 RS sector 5% · RS bench -4.5% · 1Y 8.3%9 of 12 weeks ahead 100% evidence
Exact sum: 14 + 10.8 + 9.3 + 12.9 = 47 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18Gates Industrial Corporation plcGTES 46.4/100Thin evidence · provisional56% evidence ASLEEP 14.9/35 Revenue — · PAT — · OPM change -1.9 pp 39% evidence 7.3/25 ROCE 2% · OPM 12.9% 76% evidence 11.1/20 P/E 19.2× · PEG — 15% evidence 13.1/20 RS sector 5.6% · RS bench -4% · 1Y 0.6%3 of 12 weeks ahead 100% evidence
Exact sum: 14.9 + 7.3 + 11.1 + 13.1 = 46.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19Eaton Corporation plcETN 46.1/100Mixed-negative evidence85% evidence ASLEEP 13.9/35 Revenue 15.5% · PAT -2.4% · OPM change -1.6 pp 95% evidence 11.7/25 ROCE 3.7% · OPM 16.3% 76% evidence 5.3/20 P/E 43.3× · PEG 3.02 65% evidence 15.2/20 RS sector 7.9% · RS bench -1.8% · 1Y 6.2%3 of 12 weeks ahead 100% evidence
Exact sum: 13.9 + 11.7 + 5.3 + 15.2 = 46.1 · Decision use: Price leads the evidence: RS versus the benchmark is -1.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
20A. O. Smith CorporationAOS 44.4/100Thin evidence · provisional58% evidence ASLEEP 11.9/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence 13.2/25 ROCE 6.5% · OPM 17.1% 76% evidence 11.5/20 P/E 17.4× · PEG — 15% evidence 7.8/20 RS sector -10.7% · RS bench -19% · 1Y -22.2%2 of 12 weeks ahead 100% evidence
Exact sum: 11.9 + 13.2 + 11.5 + 7.8 = 44.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21ITT Inc.ITT 43.2/100Thin evidence · provisional58% evidence ASLEEP 11.8/35 Revenue — · PAT — · OPM change -6.3 pp 45% evidence 8.6/25 ROCE 2.3% · OPM 11.7% 76% evidence 9.7/20 P/E 34.1× · PEG — 15% evidence 13.1/20 RS sector 4.2% · RS bench -5.3% · 1Y 7.4%1 of 12 weeks ahead 100% evidence
Exact sum: 11.8 + 8.6 + 9.7 + 13.1 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22Generac Holdings Inc.GNRC 43.1/100Thin evidence · provisional58% evidence ASLEEP 21.6/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence 10.2/25 ROCE 4.8% · OPM 11.1% 76% evidence 8.8/20 P/E 67.5× · PEG — 15% evidence 2.5/20 RS sector -9.7% · RS bench -18% · 1Y -3.9%1 of 12 weeks ahead 100% evidence
Exact sum: 21.6 + 10.2 + 8.8 + 2.5 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23Enpro Inc.NPO 42.6/100Mixed-negative evidence81% evidence ASLEEP 11.8/35 Revenue 10.2% · PAT -50% · OPM change -0.9 pp 83% evidence 6.3/25 ROCE 1.8% · OPM 14.4% 76% evidence 12.4/20 P/E 123.5× · PEG 0.95 65% evidence 12.1/20 RS sector 9.2% · RS bench -0.7% · 1Y 27.7%6 of 12 weeks ahead 100% evidence
Exact sum: 11.8 + 6.3 + 12.4 + 12.1 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Flowserve CorporationFLS 41.2/100Thin evidence · provisional58% evidence FADING 14.5/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence 8.2/25 ROCE 3.3% · OPM 11.2% 76% evidence 10.7/20 P/E 26× · PEG — 15% evidence 7.8/20 RS sector 2.2% · RS bench -7.4% · 1Y 27.6%3 of 12 weeks ahead 100% evidence
Exact sum: 14.5 + 8.2 + 10.7 + 7.8 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
25Pentair plcPNR 40.2/100Thin evidence · provisional58% evidence ASLEEP 15.7/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence 11.3/25 ROCE 3% · OPM 20.3% 76% evidence 11.2/20 P/E 18.9× · PEG — 15% evidence 2.0/20 RS sector -34.6% · RS bench -40.7% · 1Y -48.8%0 of 12 weeks ahead 100% evidence
Exact sum: 15.7 + 11.3 + 11.2 + 2 = 40.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26Cummins Inc.CMI 38.0/100Mixed-negative evidence85% evidence ASLEEP 8.4/35 Revenue 2.9% · PAT -7.8% · OPM change -0.7 pp 95% evidence 11.2/25 ROCE 5.2% · OPM 13.5% 76% evidence 14.1/20 P/E 36.4× · PEG 0.79 65% evidence 4.3/20 RS sector -4.1% · RS bench -13% · 1Y 24.5%1 of 12 weeks ahead 100% evidence
Exact sum: 8.4 + 11.2 + 14.1 + 4.3 = 38 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
27JBT Marel CorporationJBTM 37.9/100Mixed-negative evidence74% evidence ASLEEP 24.7/35 Revenue 78.2% · PAT — · OPM change 11.2 pp 62% evidence 5.2/25 ROCE 1% · OPM 7.3% 76% evidence 4.9/20 P/E 40× · PEG 3.63 65% evidence 3.1/20 RS sector -16.3% · RS bench -24.1% · 1Y -17.4%1 of 12 weeks ahead 100% evidence
Exact sum: 24.7 + 5.2 + 4.9 + 3.1 = 37.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -16.3% and the one-year return is -17.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
28The Middleby CorporationMIDD 37.2/100Thin evidence · provisional56% evidence ASLEEP 15.9/35 Revenue — · PAT — · OPM change 0 pp 39% evidence 8.7/25 ROCE 2.4% · OPM 15.9% 76% evidence 11.4/20 P/E 17.5× · PEG — 15% evidence 1.2/20 RS sector -17.5% · RS bench -25.2% · 1Y -16.7%1 of 12 weeks ahead 100% evidence
Exact sum: 15.9 + 8.7 + 11.4 + 1.2 = 37.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Regal Rexnord CorporationRRX 29.7/100Adverse evidence81% evidence ASLEEP 14.2/35 Revenue 1.5% · PAT 22% · OPM change -1 pp 83% evidence 5.5/25 ROCE 1.2% · OPM 10.3% 76% evidence 8.4/20 P/E 43.5× · PEG 1.94 65% evidence 1.6/20 RS sector -13.3% · RS bench -21.5% · 1Y 4%1 of 12 weeks ahead 100% evidence
Exact sum: 14.2 + 5.5 + 8.4 + 1.6 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
30Chart Industries, Inc.GTLS 26.7/100Adverse evidence71% evidence 4.7/35 Revenue -1.5% · PAT -121.4% · OPM change -9.3 pp 83% evidence 4.4/25 ROCE 0.7% · OPM 5.9% 76% evidence 8.5/20 P/E 687.4× · PEG — 15% evidence 9.1/20 RS sector -3.5% · RS bench -5.2% · 1Y 22.2%0 of 3 weeks ahead to 2026-07-17 100% evidence
Exact sum: 4.7 + 4.4 + 8.5 + 9.1 = 26.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Symbotic Inc.'s stock price today?

Symbotic Inc. trades at $43.1, −24.4% over the past year. The company is valued at $26.0 B. The stock sits at 7% of its 52-week range of $40–$84, −16.8% versus its 200-day average. On the tape, the price is in a downtrend, 1 weeks in. — as of 17 September 2026.

What were Symbotic Inc.'s latest quarterly results?

Symbotic Inc. reported revenue of $0.7 B and net profit of $0.0 B for the Jun 26 quarter. Earnings per share were $0.09. The operating margin was 4.2%, 5.9 pp higher than a year earlier. — as of 17 September 2026.

What is Symbotic Inc.'s revenue?

Symbotic Inc. reported revenue of $0.7 B in the Jun 26 quarter, +22.0% year on year. For the full FY25 fiscal year, revenue was $2.3 B (+25.7%). Over the last 4 years revenue compounded at 73.2% a year. — as of 17 September 2026.

What is Symbotic Inc.'s profit?

Symbotic Inc. earned $0.0 B of net profit in the Jun 26 quarter. Full-year FY25 profit was $−0.0 B. The operating margin ran 4.2% in the latest quarter. — as of 17 September 2026.

What is Symbotic Inc.'s market cap?

Symbotic Inc.'s market capitalisation is $26.0 B at a stock price of $43.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.

Does Symbotic Inc. pay a dividend?

No — Symbotic Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.

How is Symbotic Inc. performing?

Symbotic Inc. is in a downtrend, 1 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 17 September 2026.

Is Symbotic Inc. in an uptrend?

No — the price is in a downtrend (week 1 of stage 4), trading −16.8% versus its 200-day average and at 7% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.

Is Symbotic Inc. beating the market?

On recent form, yes — Symbotic Inc. has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.5 years the stock moved +313% against the S&P 500's +91% — ahead of the index over the full window. — as of 17 September 2026.

Will Symbotic Inc.'s stock price go up?

This page publishes no price forecast for Symbotic Inc. What it measures instead: the stock price is $43.1, the price is in a downtrend 1 weeks in. Direction is not something this site claims to know. — as of 17 September 2026.

Is the market betting against Symbotic Inc.?

Yes — short interest is 14.8% of Symbotic Inc.'s tradable float, about 9.6 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.

Does Symbotic Inc. have too much debt?

No — Symbotic Inc.'s debt-to-equity is 0.02. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 17 September 2026.

What is Symbotic Inc.'s capex?

Symbotic Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.1 B. — as of 17 September 2026.

What is Symbotic Inc.'s cash flow?

Symbotic Inc. generated $0.9 B of operating cash flow in FY25 and $0.8 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $−0.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.

How financially safe is Symbotic Inc.?

On the balance sheet, the Z-score reads 2.16 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 17 September 2026.

Where is Symbotic Inc. in its business cycle?

Symbotic Inc.'s FY25 operating margin was −3.6%, against a 5-year band of −48.0%–−3.6%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 4.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.

What could break the Symbotic Inc. story?

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.

Is Symbotic Inc. a stock worth studying right now?

This is not investment advice. The machine read: Symbotic Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-17. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI